110 related articles for article (PubMed ID: 30211813)
1. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Shah S; Luke JJ; Jacene HA; Chen T; Giobbie-Hurder A; Ibrahim N; Buchbinder EL; McDermott DF; Flaherty KT; Sullivan RJ; Lawrence DP; Ott PA; Hodi FS
Melanoma Res; 2018 Dec; 28(6):605-610. PubMed ID: 30211813
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Daud A; Kluger HM; Kurzrock R; Schimmoller F; Weitzman AL; Samuel TA; Moussa AH; Gordon MS; Shapiro GI
Br J Cancer; 2017 Feb; 116(4):432-440. PubMed ID: 28103611
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
Shoushtari AN; Ong LT; Schoder H; Singh-Kandah S; Abbate KT; Postow MA; Callahan MK; Wolchok J; Chapman PB; Panageas KS; Schwartz GK; Carvajal RD
Melanoma Res; 2016 Jun; 26(3):272-7. PubMed ID: 26795274
[TBL] [Abstract][Full Text] [Related]
4. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
5. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
6. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
7. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Jhaveri K; Chandarlapaty S; Lake D; Gilewski T; Robson M; Goldfarb S; Drullinsky P; Sugarman S; Wasserheit-Leiblich C; Fasano J; Moynahan ME; D'Andrea G; Lim K; Reddington L; Haque S; Patil S; Bauman L; Vukovic V; El-Hariry I; Hudis C; Modi S
Clin Breast Cancer; 2014 Jun; 14(3):154-60. PubMed ID: 24512858
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.
Goyal L; Chaudhary SP; Kwak EL; Abrams TA; Carpenter AN; Wolpin BM; Wadlow RC; Allen JN; Heist R; McCleary NJ; Chan JA; Goessling W; Schrag D; Ng K; Enzinger PC; Ryan DP; Clark JW
Invest New Drugs; 2020 Oct; 38(5):1533-1539. PubMed ID: 31898183
[TBL] [Abstract][Full Text] [Related]
10. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
[TBL] [Abstract][Full Text] [Related]
11. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
12. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
Tarhini AA; Frankel P; Margolin KA; Christensen S; Ruel C; Shipe-Spotloe J; Gandara DR; Chen A; Kirkwood JM
Clin Cancer Res; 2011 Oct; 17(20):6574-81. PubMed ID: 21880788
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
Goyal L; Wadlow RC; Blaszkowsky LS; Wolpin BM; Abrams TA; McCleary NJ; Sheehan S; Sundaram E; Karol MD; Chen J; Zhu AX
Invest New Drugs; 2015 Feb; 33(1):128-37. PubMed ID: 25248753
[TBL] [Abstract][Full Text] [Related]
14. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
Steeb T; Wessely A; Ruzicka T; Heppt MV; Berking C
Eur J Cancer; 2018 Nov; 103():41-51. PubMed ID: 30205280
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma.
Schmidt-Hieber M; Schmittel A; Thiel E; Keilholz U
Melanoma Res; 2004 Dec; 14(6):439-42. PubMed ID: 15577312
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Mahipal A; Tijani L; Chan K; Laudadio M; Mastrangelo MJ; Sato T
Melanoma Res; 2012 Dec; 22(6):440-6. PubMed ID: 23114504
[TBL] [Abstract][Full Text] [Related]
18. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Ny L; Jespersen H; Karlsson J; Alsén S; Filges S; All-Eriksson C; Andersson B; Carneiro A; Helgadottir H; Levin M; Ljuslinder I; Olofsson Bagge R; Sah VR; Stierner U; Ståhlberg A; Ullenhag G; Nilsson LM; Nilsson JA
Nat Commun; 2021 Aug; 12(1):5155. PubMed ID: 34453044
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
Tarhini AA; Moschos SJ; Lin Y; Lin HM; Sander C; Yin Y; Venhaus R; Gajewski TF; Kirkwood JM
Melanoma Res; 2017 Aug; 27(4):342-350. PubMed ID: 28489678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
